|
2025 Journal Article Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysisSangro, Bruno, Bouattour, Mohamed, Park, Joong-Won, Diaz, Dr. Consuelo, Erinjeri, Joseph P., Alves, Gustavo Vasconcelos, Gu, Shan-Zhi, Manikhas, Aleksei, Kuroda, Hidekatsu, Suksombooncharoen, Thatthan, Vo, Truc Hoi Trung, Ostwal, Vikas S., Eastgate, Melissa A., Vaccaro, Gina M., Griffin, Rebecca, Ali, Sajid, Balaji, Kavitha and Chan, Stephen Lam (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis. Journal of Clinical Oncology, 43 (4_suppl), 574-574. doi: 10.1200/jco.2025.43.4_suppl.574 |
|
2025 Journal Article Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in AustraliaXia, Qing, Senanayake, Sameera Jayan, Kularatna, Sanjeewa, Brain, David, McPhail, Steven M., Parsonage, Will, Eastgate, Melissa, Barnes, Annette, Brown, Nick and Carter, Hannah E. (2025). Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. Urologic Oncology, 43 (1), 62.e15-62.e26. doi: 10.1016/j.urolonc.2024.09.016 |
|
2024 Conference Publication Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe studySim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171 |
|
2024 Journal Article Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled TrialHapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2024). Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002 |
|
2024 Journal Article Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerWebb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836 |
|
2024 Journal Article Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled TrialBoyte, M. Francesca, Scanlon, Gradcert Brighid, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen Andrew, Eastgate, Melissa and Gavin, Nicole Clare (2024). Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Clinical Journal of Oncology Nursing, 28 (5), E9-E15. doi: 10.1188/24.CJON.E9-E15 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Journal Article Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocolMatthews, Robyn, Russell, Emily, Wessling, Claire, Sandler, Carolina, Eastgate, Melissa, Hajkowicz, Krispin, Pavey, Toby, Clark, Bronwyn K., Scanlon, Brighid and Gavan, Nicole C. (2024). Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. Vascular Access Journal of the Canadian Vascular Access Association, 18 (2), 44-58. doi: 10.5737/va.v18.i2.44 |
|
2023 Journal Article Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancerLee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091 |
|
2023 Conference Publication CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanomaLau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525 |
|
2023 Conference Publication Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEODay, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172 |
|
2022 Conference Publication A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitorsKhushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052 |
|
2022 Conference Publication Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospitalTurner, Cassie L. and Eastgate, Melissa (2022). Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospital. HOBOKEN: WILEY. |
|
2022 Journal Article Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysisPathmanathan, Shivanshan, Babu, Hari, Dzienis, Marcin, Azer, Mary and Eastgate, Melissa (2022). Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis. Pigment Cell and Melanoma Research, 35 (6), 587-594. doi: 10.1111/pcmr.13063 |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
|
2022 Conference Publication Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trialDay, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C. R., Nott, L. M., Van Hazel, G., Van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H. C., Jones, F. and Segelov, E. (2022). Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Electr Network, Sep 09-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2022.07.518 |
|
2022 Conference Publication Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysisPathmanathan, Shivanshan, Babu, Hari S., Dzienis, Marcin Radoslaw, Azer, Mary and Eastgate, Melissa A. (2022). Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2022 Journal Article Selective targeting of protein kinase C (PKC)-θ nuclear translocation reduces mesenchymal gene signatures and reinvigorates dysfunctional CD8+ T cells in immunotherapy-resistant and metastatic cancersDunn, Jenny, McCuaig, Robert D., Tan, Abel H. Y., Tu, Wen Juan, Wu, Fan, Wagstaff, Kylie M., Zafar, Anjum, Ali, Sayed, Diwakar, Himanshu, Dahlstrom, Jane E., Bean, Elaine G., Forwood, Jade K., Tsimbalyuk, Sofiya, Cross, Emily M., Hardy, Kristine, Bain, Amanda L., Ahern, Elizabeth, Dolcetti, Riccardo, Mazzieri, Roberta, Yip, Desmond, Eastgate, Melissa, Malik, Laeeq, Milburn, Peter, Jans, David A. and Rao, Sudha (2022). Selective targeting of protein kinase C (PKC)-θ nuclear translocation reduces mesenchymal gene signatures and reinvigorates dysfunctional CD8+ T cells in immunotherapy-resistant and metastatic cancers. Cancers, 14 (6) 1596, 1596. doi: 10.3390/cancers14061596 |
|
2021 Journal Article Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertionsJones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Mollee, P. (2021). Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. Journal of Hospital Infection, 118, 70-76. doi: 10.1016/j.jhin.2021.10.008 |
|
2021 Journal Article The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trialMolassiotis, Alex, Brown, Teresa, Cheng, Hui Lin, Byrnes, Angela, Chan, Raymond Javan, Wyld, David, Eastgate, Melissa, Yates, Patsy, Marshall, Andrea P, Fichera, Rebecca, Isenring, Liz, To, Ki Fung, Ko, Po Shan, Lam, Wang, Lam, Yuk Fong, Au, Lai Fan and Lo, Raymond See-kit (2021). The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. Nutrition Journal, 20 (1) 2, 2. doi: 10.1186/s12937-020-00657-2 |
